Focal segmental glomerulosclerosis (FSGS) is a prominent cause of kidney failure globally, necessitating dialysis for patient survival as the disease progresses. However, the current absence of FDA-approved treatments tailored specifically for treating adult and pediatric patients with FSGS poses a significant challenge to effectively managing this disease. Moreover, it is imperative for nephrologists to enhance their skills to implement practical strategies that improve the diagnostic approach for suspected FSGS cases, especially considering the profound impact of FSGS on patients' quality of life. This activity has been designed to provide practical guidance for the accurate diagnosis of FSGS and appropriate treatment selection, as well as to offer an expert assessment of the clinical trial data supporting emerging therapies in this setting.